Sep 13, 2021 / 03:00PM GMT
David Neil Lebowitz - Morgan Stanley, Research Division - VP
Good morning, and welcome to the 19th Annual Morgan Stanley Healthcare Conference. I'm one of the analysts, David Lebowitz.
Before I get started, let me begin with the requisite disclosures. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
And with that, I'm introducing this morning Karyopharm. It's an oncology company with selinexor or XPOVIO recently launched in second-line in multiple myeloma. I guess if we could get started, if you could introduce yourselves and give us a quick introduction to the company.
Richard A. Paulson - Karyopharm Therapeutics Inc. - President, CEO & Director
Sure, David. Thanks very much, and it's a pleasure to be here. I'm Richard Paulson, the CEO and President of Karyopharm.
Karyopharm Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot